Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Thought Leadership
Latest Report
Evaluate Vantage Biopharma and Venture Capital: A Deep Dive
The sheer amount of private capital available to young drug developers the last few years is nothing new, however the Covid-19 pandemic has brought about an unprecedented influx of new money into biopharma. How permanent will these new funds prove; is biopharma's importance and attributes finally being realised by investors, governments and…
Report library
Evaluate Vantage COVID-19 Report
Biopharma and Medtech are leading the fight against COVID-19, but are not immune from the significant economic impact of the pandemic. The COVID-19 pandemic is having a…
Evaluate Pharma Orphan Drug Report 2020
What will the orphan drug landscape look like in 2024? Big pharma's recent dominance of the orphan market has fuelled calls to reform the orphan drug act in the US.…
Evaluate Vantage Pharma, Biotech & Medtech 2019 in Review
2019 was a standout year for biopharma, anchored by strong fourth quarter markets and dealmaking. Following a difficult end to 2018, the biopharma industry recovered…
Evaluate Vantage 2020 Preview
The Evaluate Vantage 2020 Preview predicts a rocky year ahead, with areas of significant growth contrasting with investor uncertainty. The industry closed 2019 with a…
Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2019
Mega-deals mask a significant decline in M&A activity for pharma and medtech The Evaluate Vantage Half-Year Review 2019 summaries the most significant trends across…
